125 days, = 0.09) although this was not statistically significant (Fig. excellent outcomes to pembrolizumab compared to rapid progressors (PFS 45 days; ORR 55% vs. 25%, CBR 80% vs. 25%, median PFS 249 vs. 50 days). Using logistic regression models, PFS to ipilimumab was independently correlated Nafamostat mesylate with response to pembrolizumab Nafamostat mesylate (OR […]